Pivotal Progresses with Vascazen - Analyst Blog
16 Abril 2013 - 4:00PM
Zacks
Pivotal Therapeutics Inc. (PVTTF) recently
announced encouraging top line data from the REVEAL study (n=110)
on its cardiovascular candidate Vascazen in the US. Vascazen was
successful in achieving the primary objective of the study of
correcting Omega-3 deficiency.
Results from the study also revealed that Vascazen gained
statistical significance in several other secondary objectives in
patients having elevated triglycerides. The REVEAL trial is a
randomized, double blind, placebo controlled, multi-center study.
Pivotal Therapeutics enrolled 110 patients for the study.
The study evaluated the effects of Vascazen in the correction of
Omega-3 deficiency in patients suffering from cardiovascular
disease and having one or more risk factors associated with it.
Moreover, the concomitant effects of Vascazen on cardiovascular
risk factors including triglycerides, very-low-density lipoprotein
(VLDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and
high-density lipoprotein (HDL) cholesterol among others, were also
evaluated.
Pivotal Therapeutics stated in its press release that the positive
top line data from the REVEAL study on Vascazen has been accepted
for presentation at the American Heart Association’s
Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2013
Scientific Sessions (ATVB).
We note that the cardiovascular market currently includes big
players like Roche Holding (RHHBY) and
Sanofi (SNY).
We note that Vascazen is the lead product at Pivotal Therapeutics.
Vascazen is formulated to meet the dietary Omega-3 deficient needs
of patients suffering from cardiovascular diseases.
Pivotal Therapeutics currently carries a Zacks Rank #3 (Hold).
Meanwhile other speciality pharmaceutical companies such as
Biodel Inc. (BIOD) currently look better
positioned. Biodel carries a Zacks Rank #2 (Buy).
BIODEL INC (BIOD): Free Stock Analysis Report
PIVOTAL THERAPT (PVTTF): Get Free Report
ROCHE HLDG LTD (RHHBY): Get Free Report
SANOFI-AVENTIS (SNY): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Pivotal Therapeutics (CE) (USOTC:PVTTF)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Pivotal Therapeutics (CE) (USOTC:PVTTF)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024
Notícias em tempo-real sobre Pivotal Therapeutics Inc (CE) da OTCMarkets bolsa de valores: 0 artigos recentes
Mais Notícias de Pivotal Therapeutics (QX)